Denise Myshko

Rasonque (daraxonrasib) was approved more than six months ahead of its PDUFA date through the FDA’s National Priority Voucher pilot program.

A new study from UCLA has found that insurers saw $3,820 lower monthly costs from the use of biosimilars. Cancer patients saved $39.50 in monthly out-of-pocket costs.

Brepocitinib, now with the brand name Lisraya, treats adults with dermatomyositis, rare autoimmune disease. It is available now, but Priovant Therapeutics has not provided a list price.

University of Maryland researchers used machine learning models trained on claims data of adults with diabetes to predict monthly risk of nine acute and chronic complications.

Mounjaro is now approved for two indications: to improve blood sugar in patients with Type 2 diabetes and to lower the major adverse cardiovascular events.

University of Utah Health researchers have shown that a protein involved in cancer growth also plays a role in whether a fatty liver progresses to MASH.

Mimrylo is available now to treat adults with polycythemia vera, a blood cancer that causes the overproduction of red blood cells. It has a list price of $4,200 per vial.

A University of Pennsylvania study found that GLP-1 users with Type 2 diabetes had 37% to 68% higher hair loss rates than patients taking other diabetes medications.

PBM, employer and pharmacy leaders at the Pharmacy Benefit Management Institute annual meeting said actionable data and real-time technology, not just transparency, are needed to control rising costs.

Federal and state laws now require PBMs to report drug pricing, rebates, and prior authorization data, creating compliance challenges, said panelists PBMI's annual meeting in Orlando.